Type de Publication Article
    Titre Hepatitis C virus and HIV seroprevalences, sociodemographic characteristics, behaviors and access to syringes among drug users, a comparison of geographical areas in France, ANRS-Coquelicot 2011 survey
    Auteurs Weill-Barillet L. | Pillonel J. | Semaille C. | Léon L. | Le Strat Y. | Pascal X. | Barin F. | Jauffret-Roustide M.
    Revue Revue d'Épidémiologie et de Santé Publique
    Résumé AbstractBackground People who use drugs (PWUDs) are at a high risk for hepatitis C virus (HCV) and human immunodeficiency virus (HIV), but they have different characteristics depending on the local context. In France, seroprevalence, sociodemographic, and behavior information have only been studied at a national level rather than at a local level. The aim of this study was to describe and examine profile and drug use practice differences in seven French cities and departments and to assess whether these differences can explain HCV and HIV seroprevalence variations between French geographical areas. Methods Data were collected from the cross-sectional ANRS-Coquelicot survey conducted for the second time in 2011 among drug users having injected or snorted drugs at least once in their life. Professional interviewers administrated a face-to-face questionnaire in six different areas in France: Paris, Marseille, Bordeaux, Lille, Strasbourg and the Seine-Saint-Denis department (Paris suburbs). Participants were asked to self-collect a fingerpick blood sample in order to search for the presence of anti-HIV and anti-HCV antibodies and to estimate seroprevalence in PWUDs. Results Overall, HCV and HIV seroprevalence was 44% [95% CI: 39.6–47.9] and 10% [95% CI: 7.5–12.6] respectively. The highest HCV seroprevalence was 56% in Marseille and the lowest was 24% in Bordeaux and for HIV the highest was 18% in Seine-Saint-Denis and the lowest was 0% in Lille. The population's age differed between areas and could mostly explain HCV seroprevalence variation but not exclusively. Profiles and practices, different in each area, can also explain this variation. In multivariate analysis, HCV seroprevalence was lower in Bordeaux (prevalence ratio [PR] = 0.64), Strasbourg (PR = 0.76), and Seine-Saint-Denis (PR = 0.8) than in Paris. Nearly one-third of injectors declared having had difficulties to obtain syringes in the 6 previous months, but disparities existed between areas. Conclusion HCV risk exposure in PWUDs remains high in France and varies between different areas. Innovative harm reduction strategies including educative programs about safe injecting and supervised consumption rooms need to be developed.
    Pages 301-312
    Volume 64
    Numéro 4
    Mots clés Seroprevalence | People who use drugs | City comparison | HCV | HIV | Harm reduction | Access to syringesés | Séroprévalence | Usagers de drogues | Comparaison par ville | VHC | VIH | Réduction des risques | Accès au matériel d’injection
    Année 2016
    Url http://www.sciencedirect.com/science/article/pii/S
    Electronic resource num http://dx.doi.org/10.1016/j.respe.2015.10.003
    ISBN 0398-7620